Dianna Ammons Johnson
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2019First federal award
$3.2MFederal grants as PI8 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
8 awards · $3.2M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 16, 2025 | NIH | SBIR Phase II Late-stage Pre-clinical Development and GMP Production of a First-in-Class Extended Release IOP-lowering Formulation | $1.0M | Tavo Biotherapeutics |
| Aug 29, 2024 | NIH | SBIR Phase II Late-stage Pre-clinical Development and GMP Production of a First-in-Class Extended Release IOP-lowering Formulation | $1.1M | Tavo Biotherapeutics |
| Feb 17, 2024 | NIH | SBIR Phase I Development of a novel depot delivery system for a glaucoma therapeutic | $82K | Tavo Biotherapeutics |
| Dec 20, 2023 | NIH | SBIR Phase I Development of a novel depot delivery system for a glaucoma therapeutic | $57K | Tavo Biotherapeutics |
| Aug 31, 2023 | NIH | SBIR Phase I Development of a novel depot delivery system for a glaucoma therapeutic | $336K | Tavo Biotherapeutics |
| May 24, 2021 | NIH | SBIR Phase I Neuroprotective Properties of a Novel Glaucoma Drug and Formulation | $357K | Tavo Biotherapeutics |
| Jan 28, 2020 | NIH | SBIR Phase I Extended release formulation of a new IOP lowering drug for improved treatment of glaucoma | $55K | Tavo Biotherapeutics |
| May 28, 2019 | NIH | SBIR Phase I Extended release formulation of a new IOP lowering drug for improved treatment of glaucoma | $225K | Tavo Biotherapeutics |
Peer ranks
Federal funding#561
Awards as PI#190
Patents#273
Companies
- Tavo BiotherapeuticsLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.